Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

BACKGROUND Liver fibrosis is the main predictor of the progression of nonalcoholic fatty liver disease. Transient elastography (FibroScan), which measures liver stiffness, is a novel, noninvasive method to assess liver fibrosis. AIM We investigated the usefulness of liver stiffness measurement in the evaluation of liver fibrosis in nonalcoholic fatty liver disease patients. STUDY POPULATION A total of 97 nonalcoholic fatty liver disease patients. METHODS Transient elastography was performed for liver stiffness measurement in 97 nonalcoholic fatty liver disease patients. And the relationship between histological parameters and liver stiffness measurement was studied by multivariate analysis. Moreover, we investigated the relationship between liver stiffness measurement and the serum levels of hyaluronic acid and type IV collagen 7s domain. RESULTS The liver stiffness was well correlated with the stage of liver fibrosis (Kruskal-Wallis test p < 0.0001). The areas under the receiver-operating characteristic curves were 0.927 for > or = F1, 0.865 for > or = F2, 0.904 for > or = F3, 0.991 for > or = F4. Only fibrosis stage was correlated significantly with liver stiffness measurement by multiple regression analysis. Liver stiffness was also strongly correlated with the serum levels of type IV collagen 7s domain (r = 0.525, p < 0.0001) and hyaluronic acid (r = 0.457, p < 0.0001). CONCLUSIONS Our results show a significant correlation between liver stiffness measurement and fibrosis stage in nonalcoholic fatty liver disease patients, as confirmed by the results of liver biopsy, which remains the gold standard for evaluation of the severity of liver fibrosis in patients with nonalcoholic steatohepatitis.

[1]  P. Bedossa,et al.  Appropriateness of liver biopsy. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[2]  W D Carey,et al.  The role of liver biopsy in chronic hepatitis C , 2001, Hepatology.

[3]  M. Fink,et al.  Shear elasticity probe for soft tissues with 1-D transient elastography , 2002, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[4]  R. Soloway,et al.  Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy , 1971, The American Journal of Digestive Diseases.

[5]  T. Laurent,et al.  Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. , 1992, Scandinavian journal of clinical and laboratory investigation.

[6]  H. Kawasaki,et al.  Serum type III procollagen peptide, type IV collagen 7S domain, central triple‐helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relationship to liver histology , 1994, Hepatology.

[7]  M. Ziol,et al.  87 Prediction of liver fibrosis in non-alcoholic steatohepatitis (NASH): Risk factors and diagnostic potential of liver elasticity using fibroscan , 2006 .

[8]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[9]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[10]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[11]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[12]  B. Balkau,et al.  Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. , 1994, Journal of hepatology.

[13]  Llorenç Quintó,et al.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.

[14]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[15]  A. Nakajima,et al.  Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) , 2007, Gut.

[16]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[17]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[18]  Eugene R. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[19]  A. Sanyal.  Treatment of non‐alcoholic fatty liver disease , 2002, Journal of gastroenterology and hepatology.

[20]  B. Maharaj,et al.  SAMPLING VARIABILITY AND ITS INFLUENCE ON THE DIAGNOSTIC YIELD OF PERCUTANEOUS NEEDLE BIOPSY OF THE LIVER , 1986, The Lancet.

[21]  K. Ishak,et al.  Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. , 1988, Gastroenterology.

[22]  T. Ueno,et al.  Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. , 1992, Scandinavian journal of gastroenterology.

[23]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[24]  A. Sanyal,et al.  AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[25]  F. Kinjo,et al.  Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. , 2005, World journal of gastroenterology.

[26]  V. de Lédinghen,et al.  Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations , 2006, European journal of gastroenterology & hepatology.

[27]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[28]  Hiroyuki Kaneda,et al.  Nonalcoholic steatohepatitis: risk factors for liver fibrosis. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[30]  G. Farrell.  Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? , 2003, Journal of gastroenterology and hepatology.

[31]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[32]  M. Sato.  [Mechanical properties of living tissues]. , 1986, Iyo denshi to seitai kogaku. Japanese journal of medical electronics and biological engineering.

[33]  E. Mezey,et al.  Sampling variability on percutaneous liver biopsy. , 1979, Archives of internal medicine.

[34]  H. Saito,et al.  Efficacy of non-invasive elastometry on staging of hepatic fibrosis. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[35]  Cadranel Jf.  [Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future]. , 2002 .

[36]  S. Yamashita,et al.  Abdominal fat: standardized technique for measurement at CT. , 1999, Radiology.

[37]  Plumley Pf.  Letter: the consultants' contract. , 1975, Lancet.

[38]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.